Comprehensive medication guide to Dolutegravir/Lamivudine including estimated pricing, availability information, side effects, and how to find it in stock at your local pharmacy.
Estimated Insurance Pricing
$0–$150 copay depending on plan; commercially insured patients may pay $0/month with the ViiV Connect copay savings card. Medicare Part D covers Dovato; Extra Help (LIS) can further reduce costs. Prior authorization is commonly required.
Estimated Cash Pricing
$2,000–$3,700 retail for the brand-only Dovato tablet (30-day supply); as low as ~$3,003 with GoodRx coupons. No generic version is available in the US as of 2026.
Medfinder Findability Score
62/100
Summarize with AI
On this page
Dolutegravir/lamivudine, sold under the brand name Dovato, is a once-daily, single-tablet, complete HIV-1 treatment manufactured by ViiV Healthcare. It was first approved by the FDA on April 8, 2019 — making it the first two-drug, fixed-dose, complete regimen approved for HIV treatment-naive adults in the United States.
Each Dovato tablet contains dolutegravir 50 mg (an integrase strand transfer inhibitor, or INSTI) and lamivudine 300 mg (a nucleoside reverse transcriptase inhibitor, or NRTI). These two drugs work at different stages of the HIV replication cycle to prevent the virus from multiplying in the body.
Dovato is approved for adults and adolescents 12 years and older weighing at least 25 kg (55 lbs) who have no prior antiretroviral history, or for those who are virologically suppressed (HIV-1 RNA <50 copies/mL) on a stable regimen with no treatment failure history and no known resistance to either component.
We have a 99% success rate finding medications, even during nationwide shortages.
Need this medication?
Dovato works by blocking HIV replication at two separate points in the viral life cycle. Lamivudine, the NRTI component, blocks the reverse transcriptase enzyme — preventing HIV from converting its RNA genetic code into DNA. It does this through chain termination: lamivudine is incorporated into the growing DNA chain as a "fake" building block, halting further synthesis.
Dolutegravir, the INSTI component, blocks the integrase enzyme — preventing viral DNA from inserting itself into the host cell's chromosomes. This "strand transfer" step is essential for HIV to establish permanent infection. Dolutegravir binds directly to integrase's active site with exceptionally high affinity, giving it a high barrier to resistance.
Together, these two mechanisms create a dual blockade of HIV replication. Clinical trials (GEMINI-1, GEMINI-2) demonstrated that this two-drug approach is non-inferior to three-drug regimens in treatment-naive patients. The TANGO study validated it for virologically suppressed switch patients, and the 2025 PASO-DOBLE trial showed equivalent efficacy to Biktarvy with potentially less weight gain.
50 mg / 300 mg — tablet (film-coated)
One tablet once daily, with or without food. Each tablet contains dolutegravir 50 mg and lamivudine 300 mg. The only available dose strength.
As of early 2026, Dovato is not listed on the FDA's official drug shortage database. ViiV Healthcare continues to manufacture and distribute the product. However, Dovato is a specialty medication with a retail price of $2,000–$3,700 per month, which means most retail pharmacies do not keep it in standing inventory.
Patients commonly experience 1–3 business day delays when a pharmacy needs to order Dovato. Prior authorization from insurance companies can add additional days. HIV-specialty pharmacies and mail-order specialty pharmacies are the most reliable sources for consistent Dovato availability.
To find a pharmacy near you with Dovato in stock, use medfinder — it calls pharmacies near you and texts you the results.
Dolutegravir/lamivudine (Dovato) is not a DEA-scheduled controlled substance, so there are no special DEA prescribing requirements. Any licensed healthcare provider with prescribing authority can write a Dovato prescription within their scope of practice.
Common prescribers include:
Dovato can also be prescribed via telehealth. HIV-specialty telemedicine platforms (such as Nurx, Plume, and Folx Health) serve patients nationally and can initiate or continue Dovato prescriptions through video visit consultations. Telehealth is particularly valuable for patients in rural areas or those with transportation barriers.
No. Dolutegravir/lamivudine (Dovato) is not a DEA-scheduled controlled substance. It is a prescription medication, but there are no special DEA prescribing restrictions, monitoring programs, or quantity limits beyond standard prescription rules. Any licensed prescriber — including physicians, nurse practitioners, and physician assistants within their scope of practice — may prescribe Dovato without DEA registration constraints.
This means Dovato can also be prescribed via telehealth without the in-person visit requirements that apply to Schedule II controlled substances. This is an important advantage for patients in rural areas or those with transportation barriers who need access to HIV care.
Dovato is generally well tolerated. Common side effects occurring in at least 2% of patients in clinical trials:
Serious side effects (rare — contact your doctor immediately):
Know what you need? Skip the search.
Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide)
Three-drug, once-daily single-tablet regimen. Most prescribed HIV medication in the US. Preferred for patients with HBV co-infection. More widely available at retail pharmacies than Dovato.
Triumeq (dolutegravir/abacavir/lamivudine)
Three-drug, once-daily single-tablet regimen. Shares the same INSTI backbone (dolutegravir) as Dovato. Requires HLA-B*5701 testing before use; not for HBV co-infected patients.
Cabenuva (cabotegravir/rilpivirine)
Two-drug long-acting injectable regimen given monthly or every two months at a clinic. For virologically suppressed patients who want to eliminate daily oral pills. Eliminates pharmacy stocking issues entirely.
Juluca (dolutegravir/rilpivirine)
Two-drug, once-daily tablet. Shares dolutegravir with Dovato but pairs it with rilpivirine. Must be taken with a meal (500+ calories). For virologically suppressed patients only; contraindicated with PPIs.
Prefer Dolutegravir/Lamivudine? We can find it.
Dofetilide (Tikosyn)
majorContraindicated. Dolutegravir inhibits OCT2 renal transporter, dramatically increasing dofetilide levels and causing potentially fatal cardiac arrhythmias.
Rifampin
majorSignificantly reduces dolutegravir levels. If unavoidable, supplement with additional dolutegravir 50 mg 12 hours after Dovato.
Carbamazepine (Tegretol)
majorReduces dolutegravir levels through enzyme induction. Supplement with additional dolutegravir 50 mg 12 hours after Dovato if coadministration is necessary.
St. John's Wort
majorHerbal supplement that significantly reduces dolutegravir blood levels. Should be avoided entirely during Dovato treatment.
Metformin
moderateDolutegravir inhibits OCT2/MATE1 transporters, increasing metformin levels. Monitor for metformin toxicity; dose adjustment may be needed.
Polyvalent cation antacids (aluminum, magnesium, calcium)
moderateChelation reduces dolutegravir absorption. Take Dovato 2 hours before or 6 hours after these products.
Iron and calcium supplements
moderateReduce dolutegravir absorption if not taken with food. Take with food alongside Dovato, or 2 hours before/6 hours after without food.
Dolutegravir/lamivudine (Dovato) is one of the most important HIV treatments to emerge in recent years. As the first two-drug, single-tablet, complete HIV regimen, it demonstrated that fewer drugs could be just as effective as three — a paradigm shift in antiretroviral therapy. Years of clinical trial data, including the GEMINI trials, TANGO, and PASO-DOBLE, have confirmed its efficacy and favorable tolerability profile.
The main challenges with Dovato are practical: its specialty drug status means it isn't always on pharmacy shelves, and its retail price requires most patients to use insurance or manufacturer assistance programs. But with the right tools and proactive planning, most patients can access Dovato reliably and affordably.
If you're struggling to find Dovato at your pharmacy, medfinder can help by calling pharmacies near you to check current stock and texting you the results. Never miss a dose — your health depends on staying on treatment consistently.
Medfinder Editorial Standards
Our medication guides are researched and written to help patients make informed decisions. All content is reviewed for accuracy and updated regularly. Learn more about our standards
ChatGPT
Claude
Perplexity
Grok
Gemini